We are live on
!
Find out more
ESPR
Esperion Therapeutics
ESPR
ESPR
Delisted
ESPR was delisted on the 10th of July, 2026.
136 hedge funds and large institutions have $352M invested in Esperion Therapeutics in 2022 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 42 increasing their positions, 42 reducing their positions, and 18 closing their positions.
New
Increased
Maintained
Reduced
Closed
417% more call options, than puts
Call options by funds: $14.4M | Put options by funds: $2.78M
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
46% more capital invested
Capital invested by funds: $241M → $352M (+$111M)
33% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 18
5.14% more ownership
Funds ownership: 82.66% → 87.8% (+5.1%)
3% more funds holding
Funds holding: 132 → 136 (+4)
0% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 42
Holders
136
Holders Change
+4
Holders Change %
+3.03%
% of All Funds
2.29%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.05%
New
24
Increased
42
Reduced
42
Closed
18
Calls
$14.4M
Puts
$2.78M
Net Calls
+$11.6M
Net Calls Change
+$5.74M
Top Buyers
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
+$11.6M |
| 2 |
Millennium Management
New York
|
+$8.27M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$6.03M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
+$4.79M |
| 5 |
BlackRock
New York
|
+$3.01M |
